Cambridge, U.K., 9th September 2020 – Cycle is proud to announce that Dr David Buckeridge has joined Cycle’s Board of Directors as Non Executive Director.
Dr Buckeridge has successfully led management teams through the challenges of business growth and is a Board member and adviser of the highest calibre. The Cycle team looks forward to working with David as we continue to build our business through focusing on the needs of rare disease patients.
Non Executive Director – Cycle Pharmaceuticals
Dr. Buckeridge has 35 years of operational management experience in the life science and agribusiness industries. After serving as Group CEO of Advanta BV, the largest independent agronomic seed business in the world at that time, David led its highly successful exit from private equity ownership to a strategic Asian buyer and then advised on preparation for its successful IPO to the Indian stock market in 2007. Subsequently, he has played a senior advisory role to both strategic and financial investors in his core sectors, focusing on the operational and strategic planning aspects of these industries.
He began his career with the multinational pharmaceutical company AstraZeneca, spending approximately 20 years in a variety of management positions globally.
He has served as director and Chairman of a range of companies in the agribusiness, pharma, and public health industries. Currently, Dr. Buckeridge serves on the Boards of ScanBio Marine Group, Spearhead International, Rivulis, and Verdesian Life Sciences. He is also an independent director of Velcourt Ltd, the UK’s largest farm management company.
He has a Bachelor of Science and Ph.D. in Genetics and Plant Sciences from the University of Wales (U.K.)
Please visit Cycle’s Board of Directors page to learn more